Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

P1‐049: Exploiting blood transcriptome for gene and pathway identification in Alzheimer's disease
Allen, Mariet , Wang, Xue , Serie, Daniel, Strickland, Samantha L. , Nguyen, Thuy , Malphrus, Kimberly G., Lincoln, Sarah, Carrasquillo, Minerva M. , Schellenberg, Gerard D. , Lowe, Val J. , Younkin, Steven G. , Asmann, Yan W. , Petersen, Ronald C. , Taner, Nilüfer, Burgess, Jeremy D. , Carrasquillo, Minerva M. , Crook, Julia E. , Knopman, David S. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | December 15, 2015 | Volume: 11 | Issue: 7S_Part_7 | Pages: No page available

10.1016/j.jalz.2015.06.245 Get It

Progression of Nonradiographic Axial Spondyloarthritis to Ankylosing Spondylitis: A Population‐Based Cohort Study
Gabriel, Sherine E., Wang, Runsheng , Ward, Michael M.

Mayo Clinic

Arthritis & Rheumatology | December 14, 2015 | Volume: 68 | Issue: 6 | Pages: 1415-1421

10.1002/art.39542 | PMID 26663907 Get It

ObjectiveThe long‐term outcome of patients with nonradiographic axial spondyloarthritis (SpA) is unclear, particularly whether few or most progress to ankylosing spondylitis (AS). Our objective was to examine the progression to AS in a population‐based inception cohort of patients with nonradiographic axial SpA.MethodsThe Rochester Epidemiology Project (REP) is a longstanding population‐based study of health in the residents of Olmsted County, Minnesota. We searched the REP from 1985 to 2010 using diagnostic and procedural codes for back pain, HLA–B27, and magnetic resonance imaging of the pelvis, and we performed detailed chart reviews to identify subjects who fulfilled the Assessment of SpondyloArthritis international Society classification criteria for axial SpA but did not have AS. We followed these subjects from disease onset to March 15, 2015, and used survival analysis to measure the time to progression to AS.ResultsAfter screening 2,151 patients, we identified 83 subjects with new‐onset nonradiographic axial SpA. Over a mean follow‐up of 10.6 years, progression to AS occurred in 16 patients. The probability that the condition would remain as nonradiographic axial SpA at 5, 10, and 15 years was 93.6%, 82.7%, and 73.6%, respectively. There was more frequent and more rapid progression among subjects in the imaging arm (n = 18) than among those in the clinical arm (n = 65) (28% versus 17%; hazard ratio 3.50 [95% confidence interval 1.15–10.6], P = 0.02).ConclusionProgression to AS occurred in a minority (26%) of patients with nonradiographic axial SpA over as long as 15 years of follow‐up. This suggests that the classification criteria for nonradiographic axial SpA identifies many patients in whom the condition is unlikely to progress to AS or that nonradiographic axial SpA represents a prolonged prodromal state that takes longer to evolve to AS and thus requires longer follow‐up.
Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine
Burns, Ted M., Smith, Gordon, Allen, Jeffrey A. , Amato, Anthony A. , Arnold, W. David , Barohn, Richard J., Benatar, Michael , Bird, Shawn J. , Bromberg, Mark B. , Chahin, Nizar, Ciafaloni, Emma , Corse, Andrea M. , David, William S., Dimberg, Elliot L., Sousa, De , Donofrio, Peter D., Dyck, P. James B. , Engel, Andrew G. , Ensrud, Erik , Ferrante, Mark A., Freimer, Miriam , Gable, Karissa , Gibson, Summer, Gilchrist, James M. , Goldstein, Jonathan , Gooch, Clifton L. , Goodman, Brent P., Gorelov, Dmitri, Gospe, Sídney M. , Goyal, Namita , Guidon, Amanda C. , Guptill, Jeffrey T. , Gutmann, Laurie , Gutmann, Ludwig , Gwathmey, Kelly , Harati, Yadollah, Harper, C. Michel , Hehir, Michael K. , Hobson‐Webb, Lisa D., Howard, James F. , Jackson, Carlayne E. , Jones, Sarah , Juel, Vern C. , Kaminski, Henry J. , Kennelly, Kathleen D., Khella, Sami, Khoury, Julie, Kincaid, John C., Kissel, John T., Kolb, Noah , Lacomis, David , Larriviere, Daniel G., Lewis, Richard A. , Litchy, William J. , Logigian, Eric L. , Lou, Jau-Shin, MacGowen, Daniel J.L., Maselli, Ricardo A. , Massey, Janice M., Mauermann, Michelle L. , Mathews, Katherine D. , Meriggioli, Matthew N. , Moon, Joon-Shik, Mozaffar, Tahseen , Nations, Sharon , Ostrow, Lyle W. , Pascuzzi, Robert M. , Peltier, Amanda , Ruzhansky, Katherine , Ross, Mark A., Rubin, Devon I., Russell, James A., Sachs, George, Salajegheh, Mohammad, Saperstein, David , Scelsa, Stephen N. , Selcen, Duygu , Shaibani, Aziz , Silvestri, Nicholas J. , Singleton, J. Rob, Smith, Benn E., So, Yuen T., Solórzano, Guillermo, Sorenson, Eric J. , Srinivasen, Jayashri, Tavee, Jinny , Tawil, Rabi , Thaisetthawatkul, Pariwat , Thornton, Charles A. , Trivedi, Jaya , Vernino, Steven , Wang, Annabel K., Webb, Tyler A., Weiss, Michael D. , Windebank, Anthony J. , Wolfe, Gil I. , Crum, Brian A. , Dimberg, Elliot, Chahin, Nizar, Cohen, Jeffrey Allen , Johnson, Nicholas E , Karam, Chafic , Ladha, Shafeeq , Li, Yuebing , Miller, Robert G. , Nowak, Richard J. , Richman, David P. , Shieh, Perry B. , Kolb, Noah A , Mauermann, Michelle L , Gutmann, Laurie , Allen, Jeffrey A , Arnold, W David , Vernino, Steven , Kaminski, Henry

Mayo Clinic

Muscle & Nerve | December 13, 2015 | Volume: 53 | Issue: 2 | Pages: 165-168

10.1002/mus.25009 | PMID 26662952 Get It

A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG‐ACRIN cancer research group (E1908)
Wang, Victoria , Ketterling, Rhett P. , Hanson, Curtis A. , Libby, Edward N., Call, Timothy G. , Chang, Julie E., Liu, Jane J., Calvo, Alejandro , Rowe, Jacob M. , Luger, Selina M. , Litzow, Mark R. , Tallman, Martin S. , Zent, Clive S. , Barrientos, Jacqueline C. , Chang, Julie E., Lazarus, Hillard M. , Ketterling, Rhett P

Mayo Clinic

American Journal of Hematology | December 11, 2015 | Volume: 91 | Issue: 3 | Pages: 308-312

10.1002/ajh.24265 | PMID 26662208 Get It

Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) patients requiring initial therapy are often older and frailer and unsuitable candidates for standard chemoimmunotherapy regimens. Shorter duration combination monoclonal antibody (mAb) therapy using alemtuzumab and rituximab has been shown to be effective and tolerable treatment for CLL. Standard dose anti‐CD20 mAb therapy causes loss of CD20 expression by surviving CLL cells, which can be minimized by decreasing the mAb dose. We report a randomized phase II clinical trial enrolling older (≥ 65 years) patients (median age 76 years, n = 31) with treatment naïve progressive CLL. Patients received 8‐12 weeks of standard subcutaneous alemtuzumab with either intravenous standard (375 mg/m2 weekly)(n = 16) or low dose (20 mg/m2 3x week)(n = 15) rituximab. This study was closed before full accrual because the manufacturer withdrew alemtuzumab for treatment of CLL. The overall response rate was 90% with an 45% complete response rate, median progression‐free survival of 17.9 months and no significant differences in outcome between the low and standard dose rituximab arms. The major toxicities were cytopenia and infection with one treatment fatality caused by progressive multifocal leukoencephalopathy but no other opportunistic infections. Combination mAb therapy was effective and tolerable treatment for older and frailer patients with progressive CLL, achieving a high rate of complete remissions. These data support the role of mAb in therapy for less fit CLL patients and the further study of low dose higher frequency anti‐CD20 mAb therapy as a potentially more effective use of anti‐CD20 mAb in the treatment of CLL. Am. J. Hematol. 91:308–312, 2016. © 2015 Wiley Periodicals, Inc.
Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer
Roberts, Nicholas J. , Norris, Alexis L. , Petersen, Gloria M. , Bondy, Melissa L. , Gallinger, Steven , Kurtz, Robert C. , Olson, Sara H. , Rustgi, Anil K. , Schwartz, Ann G. , Zogopoulos, George , Ali, Syed Z. , Axilbund, Jennifer E., Chaffee, Kari G. , Childs, Erica J., Herman, Joseph M. , Kramer, Melissa , Makohon-Moore, Alvin P. , McCombie, W. Richard , McMahon, K. Wyatt, Niknafs, Noushin , Parla, Jennifer, Pirooznia, Mehdi , Potash, James B. , Rhim, Andrew D. , Smith, Alyssa , Wolfgang, Christopher L. , Wood, Laura D. , Zandi, Peter P. , Karchin, Rachel , Eshleman, James R. , Papadopoulos, Nickolas , Kinzler, Kenneth W. , Vogelstein, Bert , Hruban, Ralph H. , Rabe, Kari G. , Brand, Randall E. , Stoffel, Elena M. , Syngal, Sapna , Chen, Yunching , Coté, Michele L. , Douville, Christopher , Goes, Fernando , Iacobuzio–Donahue, Christine A. , Wang, Yuxuan , Goggins, Michael , Klein, Alison P. , Pirooznia, Mehdi

Mayo Clinic

Cancer Discovery | December 9, 2015 | Volume: 6 | Issue: 2 | Pages: 166-175

10.1158/2159-8290.cd-15-0402 | PMID 26658419 Get It

Abstract Pancreatic cancer is projected to become the second leading cause of cancer-related death in the United States by 2020. A familial aggregation of pancreatic cancer has been established, but the cause of this aggregation in most families is unknown. To determine the genetic basis of susceptibility in these families, we sequenced the germline genomes of 638 patients with familial pancreatic cancer and the tumor exomes of 39 familial pancreatic adenocarcinomas. Our analyses support the role of previously identified familial pancreatic cancer susceptibility genes such as BRCA2, CDKN2A, and ATM, and identify novel candidate genes harboring rare, deleterious germline variants for further characterization. We also show how somatic point mutations that occur during hematopoiesis can affect the interpretation of genome-wide studies of hereditary traits. Our observations have important implications for the etiology of pancreatic cancer and for the identification of susceptibility genes in other common cancer types. Significance: The genetic basis of disease susceptibility in the majority of patients with familial pancreatic cancer is unknown. We whole genome sequenced 638 patients with familial pancreatic cancer and demonstrate that the genetic underpinning of inherited pancreatic cancer is highly heterogeneous. This has significant implications for the management of patients with familial pancreatic cancer. Cancer Discov; 6(2); 166–75. ©2015 AACR. This article is highlighted in the In This Issue feature, p. 109
TRIM72 modulates caveolar endocytosis in repair of lung cells
Nagre, Nagaraja N. , Wang, Shaohua , Kellett, Thomas, Kanagasabai, Ragu, Deng, Jing, Nishi, Miyuki , Shilo, Konstantin , Oeckler, Richard A. , Yalowich, Jack C. , Takeshima, Hiroshi , Christman, John W. , Hubmayr, Rolf D., Zhao, Xiaoli

Mayo Clinic

American Journal of Physiology-Lung Cellular and Molecular Physiology | December 4, 2015 | Volume: 310 | Issue: 5 | Pages: L452-L464

10.1152/ajplung.00089.2015 | PMID 26637632 Get It

Alveolar epithelial and endothelial cell injury is a major feature of the acute respiratory distress syndrome, in particular when in conjunction with ventilation therapies. Previously we showed [Kim SC, Kellett T, Wang S, Nishi M, Nagre N, Zhou B, Flodby P, Shilo K, Ghadiali SN, Takeshima H, Hubmayr RD, Zhao X. Am J Physiol Lung Cell Mol Physiol 307: L449–L459, 2014.] that tripartite motif protein 72 (TRIM72) is essential for amending alveolar epithelial cell injury. Here, we posit that TRIM72 improves cellular integrity through its interaction with caveolin 1 (Cav1). Our data show that, in primary type I alveolar epithelial cells, lack of TRIM72 led to significant reduction of Cav1 at the plasma membrane, accompanied by marked attenuation of caveolar endocytosis. Meanwhile, lentivirus-mediated overexpression of TRIM72 selectively increases caveolar endocytosis in rat lung epithelial cells, suggesting a functional association between these two. Further coimmunoprecipitation assays show that deletion of either functional domain of TRIM72, i.e., RING, B-box, coiled-coil, or PRY-SPRY, abolishes the physical interaction between TRIM72 and Cav1, suggesting that all theoretical domains of TRIM72 are required to forge a strong interaction between these two molecules. Moreover, in vivo studies showed that injurious ventilation-induced lung cell death was significantly increased in knockout (KO) TRIM72KO and Cav1KO lungs compared with wild-type controls and was particularly pronounced in double KO mutants. Apoptosis was accompanied by accentuation of gross lung injury manifestations in the TRIM72KO and Cav1KO mice. Our data show that TRIM72 directly and indirectly modulates caveolar endocytosis, an essential process involved in repair of lung epithelial cells through removal of plasma membrane wounds. Given TRIM72's role in endomembrane trafficking and cell repair, we consider this molecule an attractive therapeutic target for patients with injured lungs.
Complementary and Integrative Medicine at Mayo Clinic
Pang, Ran , Wang, Shihan , Tian, Lin , Lee, Mark C. , Do, Alexander , Cutshall, Susanne M. , Li, Guangxi , Bauer, Brent A. , Thomley, Barbara S. , Chon, Tony Y. , Li, Guangxi

Mayo Clinic

The American Journal of Chinese Medicine | December 1, 2015 | Volume: 43 | Issue: 08 | Pages: 1503-1513

10.1142/s0192415x15500858 | PMID 26621439 Get It

Complementary and alternative medicine (CAM) has gained acceptance throughout the industrialized world. The present study was performed to provide information about the use of CAM at Mayo Clinic, an academic medical center in Northern Midwest of the US. We retrospectively reviewed the electronic medical records of 2680 patients visiting the CAM program at Mayo Clinic, Rochester, between 1 July 2006 and 31 March 2011. Services provided included acupuncture, massage, integrative medical consultations and executive stress management training. Data including age, gender, race, diagnosis and the number of treatment/consultation sessions were collected to describe the use of CAM in our institute over the last several years. It was found that the mean (standard deviation) age of patient was 52.6 (15.5) years. Of those, 73.1% were female and 26.9% were male. Most patients were white. The number of patients referred to CAM increased significantly from 2007 to 2010. The three most common diagnostic categories were back pain (12.9%), psychological disorders (11.8%), and joint pain (9.6%). Back pain was the most common diagnosis for patients receiving acupuncture, and fibromyalgia was the most common for patients receiving massage therapy. Psychological disorders (i.e., stress) were the major diagnosis referred to both integrative medical consults and executive stress management training. These results suggest that the diseases related to pain and psychological disorders are the main fields of CAM use. It also shows the increasing trend of the use of CAM at an academic medical center in the US.
Negative correlation of ITCH E3 ubiquitin ligase and miRNA-106b dictates metastatic progression in pancreatic cancer
Luo, Zhu-lin, Luo, Huijun , Cheng, Long , Huang, Zhu , Dai, Ruiwu , Tian, Fuzhou, Wang, Tao , Tang, Lijun , Luo, Hui-Jun, Chen, Fang Joe , Li, Kun

Mayo Clinic

Oncotarget | November 26, 2015 | Volume: 7 | Issue: 2 | Pages: 1477-1485

10.18632/oncotarget.6395 | PMID 26621835 Get It

Histopathologic Evaluation of Adipose Autografts in a Rabbit Ear Model
Bartynski, Jeffrey, Marion, Mitchell S., Wang, Tom D., Bartynski, Jeffrey M.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | November 25, 2015 | Volume: 102 | Issue: 4 | Pages: 314-321

10.1177/019459989010200402 | PMID 2136268 Get It

Injection of autologous adipose tissue removed via liposuction has been used clinically for facial contouring, the aging face, furrows, facial atrophy, acne scars, nasolabial folds, chin, and various other surgical defects. Survival rates for autografts of fat have been quoted anywhere from 30% to 80%. Our study uses a reproducible rabbit animal model for autotransplantation of adipose tissue and examines the histopathologic changes that occur to the graft over time. Autogenous subcutaneous fat was removed from a dorsal scapular donor site, treated to stimulate cannula damage as in liposuction, then reinjected at the base of the ear. Histologic examination of the grafts were made at 5, 10, 15, 20, 40, and 100 days after transplantation. Hematoxylin‐eosin sections were graded on degree of fibrosis present (0 to 4+), viable fat (1 to 10), degree of inflammation (0 to 4+), and neovascularization (+ or ‐). Viability of fat decreased from 8.5 to 10 at 5 days to 2 viability at 40 days. Acute inflammation peaked at 10 days, followed by the chronic inflammatory response with macrophages and multinucleated giant cells scavenging the dying fat graft. Neovascularization began at 5 days, peaked at 10 days, and remained constant thereafter only at the edge of the graft. Microcysts appeared at 15 days and increased in number in proportion to the decrease in viable fat. In summary, the temporal histologic events are progressive fibrosis; decreased amount of viable fat; inflammation beginning with a neutrophilic response, later a macrophage and giant cell response; and neovascularization at the periphery of the graft insufficient to maintain graft viability. In our animal model, autografts of fat appear to have limited long‐term viability and are replaced by fibrous tissue. This may have clinical implications in autografting of fat in facial plastic and reconstructive surgery.